As we uncover new targets and strategies in the ever-evolving landscape of cancer resistance, the role of preclinical animal systems becomes paramount. Accurately pairing a promising target with the most suited patient group necessitates not only an extensive array of tools and profound expertise but also animal models that mirror the patient's clinical scenario right from the in vitro phase of preclinical drug progression.
With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically-predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.
This workshop will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.
Registration for the event is required. Attendance for the workshop is free and lunch will be served, but spaces are limited. We encourage you to register early.